Eng

China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals

South China Morning Post
發布於 2020年01月29日00:01 • Elizabeth Cheung elizabeth.cheung@scmp.com
  • HKU’s Professor Yuen Kwok-yung says his team is working on vaccine, having isolated virus from the city’s first imported case
  • Scientists in mainland China and the United States are also racing to produce a vaccine for the deadly new coronavirus
The previously unknown coronavirus has killed more than 100 people and infected thousands. Photo: National Microbiology Data Centre

Hong Kong researchers have already developed a vaccine for the deadly Wuhan coronavirus " but need time to test it, according to infectious diseases expert Professor Yuen Kwok-yung.

Scientists in mainland China and the United States were also separately racing to produce a vaccine for the new coronavirus, which has killed more than 100 people and infected thousands.

廣告(請繼續閱讀本文)

Yuen, chair of infectious diseases at the University of Hong Kong, revealed that his team was working on the vaccine and had isolated the previously unknown virus from the city's first imported case.

"We have already produced the vaccine, but it will take a long time to test on animals," Yuen said, without giving a specific time frame on when it would be ready for patients.

Professor Yuen Kwok-yung did not give a time frame on when the vaccine would be ready. Photo: Winson Wong
廣告(請繼續閱讀本文)

But he said it would take months to test the vaccine on animals and at least another year to conduct clinical trials on humans before it was fit for use.

HKU researchers based it on a nasal spray influenza vaccine previously invented by Yuen's team.

Researchers modified the flu vaccine with part of the surface antigen of the coronavirus, meaning it could prevent influenza viruses as well as the new coronavirus, which causes pneumonia.

廣告(請繼續閱讀本文)

Hong Kong slashes cross-border travel with mainland China amid virus outbreak

The vaccine, if successfully tested, could be the answer to a disease that has infected more than 4,600 people globally and killed over 100 on the mainland, mostly in Wuhan, centre of the outbreak.

Hong Kong had so far seen eight confirmed cases. From noon on Monday to noon on Tuesday, 78 more people were reported as suspected cases. Currently, 103 people are in isolation in public hospitals.

Although mainland media quoted Chinese infectious diseases expert Li Lanjuan on Monday as saying a vaccine targeting the coronavirus was being developed and could be made in around a month at the earliest, Yuen expressed doubts.

He said the one being developed on the mainland is likely to be an inactivated virus vaccine, which consists of a virus grown in a culture that has had its infectivity destroyed by chemicals or radiation.

To test the vaccine, it will have to be injected into an animal to see if it produces a good immune response, Yuen said. The vaccinated animal would then be exposed to the virus to see if is protected.

Coronavirus: Beijing Sars hospital to reopen as death toll passes 100

"If the vaccine appears effective and safe in a number of animal species, it will go into clinical trials on humans. This takes at least one year even if expedited," Yuen said.

He was also concerned that the approach taken by the mainland side to develop a vaccine would lead to a major complication, in which people who were vaccinated might develop a more severe disease if exposed to the virus. He said such a reaction for coronavirus had been recorded in reports.

Coronaviruses are a large family of viruses causing illnesses ranging from the common cold to more severe diseases such as Middle East respiratory syndrome (Mers) and severe acute respiratory syndrome (Sars).

Meanwhile, Xinhua reported that Shanghai East Hospital of Tongji University had urgently approved a project for the development of a vaccine targeting the novel virus.

What you need to know about the coronavirus in China

The vaccine will be co-developed by the hospital and Stemirna Therapeutics, a Shanghai-based biotechnology company, the report said.

Company CEO Li Hangwen said no more than 40 days would be needed to manufacture vaccine samples, which will then be sent for tests and brought to clinics "as soon as possible".

Copyright (c) 2020. South China Morning Post Publishers Ltd. All rights reserved.

查看原始文章

更多 Eng 相關文章

China sees nearly 300 mln domestic tourist trips during May Day holiday
XINHUA
Xinhua News | China box office surpasses 1.5 bln yuan during May Day holiday
XINHUA
Ancient cultural street protection in water town in east China
XINHUA
Highlights of Xi's state visit to France
XINHUA
Xi aims to open brighter future of China-France ties via visit
XINHUA
Rockets from Lebanon hit N. Israel, causing power outages
XINHUA
Global Times: Xi starts state visit to France, commends bilateral relations
PR Newswire (美通社)
Huawei Launches a Series of F5G-A Products and Solutions to Enable Industrial Intelligence in Asia Pacific
PR Newswire (美通社)
Update: China sees nearly 300 mln domestic tourist trips during May Day holiday
XINHUA
Foreign-invested enterprises propel Shanghai's lithium battery exports
XINHUA
Xi Jinping, "a sincere friend of Serbia"
XINHUA
More than 25,000 Global Leaders and Industry Decision Makers Gather at Asia Tech x Singapore to Forge an Inclusive Digital Future
PR Newswire (美通社)
ZTE's science-based targets approved by SBTi
PR Newswire (美通社)
Successful Conclusion of SOUEAST Motor Global Investment Promotion Conference: Launching a New Chapter in Globalization Strategy
PR Newswire (美通社)
Xinhua Photo Daily | May 6, 2024
XINHUA
Revenues of Chinese SOEs up 3.2 pct in first 3 months
XINHUA
GLOABLink | China-EU green energy partnership drives sustainable development across borders
XINHUA
Interview: Participation in BRI boosts Serbia's overall development -- official
XINHUA
China expects 18.65 mln railway trips on last day of May Day holiday
XINHUA
GLOBALink | China-France forum underscores people-to-people, cultural exchanges
XINHUA
Xi arrives in Paris for state visit to France
XINHUA
Xi receives warm welcome as he arrives in Paris for state visit
XINHUA
Palm Oil Giant Musim Mas Pledges Third Tranche of S$5 million In Boost to Local Charities
PR Newswire (美通社)
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
PR Newswire (美通社)
Giovanni Sordo Barolo wine dinner at Castellana
Tatler Hong Kong
Lake Resources Signs Letter of Intent with Argentine Energy Infrastructure Company YPF Luz for Kachi Power Supply
PR Newswire (美通社)
Moments in Motion | Xi receives warm welcome as he arrives in Paris for state visit
XINHUA
Interview: China an important market for multinational companies, says FGS Global CEO
XINHUA
China handles nearly 8.47 mln entry-exit trips during May Day holiday
XINHUA
Healthplex Expo, Natural & Nutraceutical Products China 2024 to Shine in Shanghai in June
PR Newswire (美通社)
Interview: Saudi Arabia expects 5 mln Chinese tourists by 2030, says tourism official
XINHUA